Research Analysts’ Recent Ratings Updates for Tocagen (TOCA)

A number of research firms have changed their ratings and price targets for Tocagen (NASDAQ: TOCA):

  • 5/15/2017 – Tocagen is now covered by analysts at Leerink Swann. They set a “mkt perform” rating and a $19.00 price target on the stock.
  • 5/15/2017 – Tocagen is now covered by analysts at Stifel Nicolaus. They set a “buy” rating and a $24.00 price target on the stock.
  • 5/9/2017 – Tocagen had its “outperform” rating reaffirmed by analysts at Evercore ISI. They now have a $28.00 price target on the stock.
  • 5/8/2017 – Tocagen is now covered by analysts at Stifel Nicolaus. They set a “buy” rating and a $24.00 price target on the stock.
  • 5/8/2017 – Tocagen is now covered by analysts at Leerink Swann. They set a “market perform” rating and a $19.00 price target on the stock.

Shares of Tocagen Inc (NASDAQ:TOCA) traded up 5.99% during mid-day trading on Friday, reaching $15.74. 28,903 shares of the company’s stock traded hands. The firm’s 50-day moving average is $15.06 and its 200 day moving average is $15.06. The firm’s market cap is $34.66 million. Tocagen Inc has a one year low of $10.25 and a one year high of $17.95.

In other Tocagen news, Director Paul Schimmel bought 10,000 shares of the stock in a transaction dated Wednesday, April 19th. The shares were acquired at an average cost of $10.00 per share, for a total transaction of $100,000.00. Following the completion of the transaction, the director now owns 23,464 shares in the company, valued at approximately $234,640. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Harry E. Gruber bought 25,000 shares of the stock in a transaction dated Wednesday, April 19th. The shares were acquired at an average price of $10.00 per share, for a total transaction of $250,000.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 42,500 shares of company stock worth $425,000.

Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.

5 Day Chart for NASDAQ:TOCA

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/research-analysts-recent-ratings-updates-for-tocagen-toca/1836102.html

Receive News & Ratings for Tocagen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *